Imatinib mesylate--uncovering a fast track to adaptive immunity.
Smyth
Mark J
MJ
Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
D019264:Adoptive Transfer; D000818:Animals; D001549:Benzamides; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000145:classification / Q000276:immunology*; D000068877:Imatinib Mesylate; D007371:Interferon-gamma / Q000096:biosynthesis; D007372:Interferons / Q000096:biosynthesis*; D007694:Killer Cells, Natural / Q000276:immunology*; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D010879:Piperazines / Q000276:immunology* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000276:immunology* / Q000627:therapeutic use
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D007371:Interferon-gamma; D000068877:Imatinib Mesylate; D007372:Interferons; D011505:Protein-Tyrosine Kinases